Suppr超能文献

新型抗心律失常药物西苯唑啉在人体中的药代动力学

Pharmacokinetics in man of a new antiarrhythmic drug, cibenzoline.

作者信息

Canal M, Flouvat B, Tremblay D, Dufour A

出版信息

Eur J Clin Pharmacol. 1983;24(4):509-15. doi: 10.1007/BF00609894.

Abstract

The kinetics of cibenzoline (UP 339.01), a new antiarrhythmic drug, was studied after i.v. and oral administration to 5 healthy subjects. Cibenzoline levels in plasma and urine cibenzoline were measured by a GLC method. After i.v. administration, the total clearance was 826 ml . min-1. The fraction of cibenzoline excreted unchanged in the urine was 0.602 and it was correlated with the creatinine clearance. After i.v. and oral administration, the renal clearances were 499 ml . min-1 and 439 ml . min-1, and the half-lives were 4 h 01 min and 3 h 24 min, respectively. The differences were not significant. Availability by the oral route was 0.92, the maximum plasma concentration being observed at 1 h 36 min. The results were compared with those for other antiarrhythmic drugs.

摘要

对5名健康受试者静脉注射和口服新型抗心律失常药物西苯唑啉(UP 339.01)后的动力学进行了研究。采用气相色谱法测定血浆中西苯唑啉水平和尿中西苯唑啉含量。静脉注射后,总清除率为826 ml·min⁻¹。尿中以原形排泄的西苯唑啉分数为0.602,且与肌酐清除率相关。静脉注射和口服后,肾清除率分别为499 ml·min⁻¹和439 ml·min⁻¹,半衰期分别为4小时01分钟和3小时24分钟。差异不显著。口服途径的生物利用度为0.92,在1小时36分钟时观察到最大血浆浓度。将结果与其他抗心律失常药物的结果进行了比较。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验